Cellular Biomedicine Group To Present At Chinabio Partnering Forum In Shanghai On April 16, 2015

SHANGHAI, China and PALO ALTO, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, announced that they have been selected to present at the seventh annual ChinaBio® Partnering Forum 2015 to be held in Shanghai (April 15–16, 2015) at the Kerry Hotel Pudong in Shanghai, China. This life science industry event is expected to attract over 800 attendees from around the world focused on developing cross-border relationships in China.

Companies were selected to present based on their products, technologies or services providing high-value to multinational or domestic companies doing business in China. William (Wei) Cao, PhD, BM, Chief Executive Officer of the Company, will present "Realizing the Potential ofCell-Based Therapy Technology" on April 16th at 3:15pm.

Cellular Biomedicine Group will be available during the event for one-to-one meetings scheduled via EBD Group's partneringONE® system, and the Company's exhibition space can be found at booth 1101.

More information on the ChinaBio® Partnering Forum is available at www.CBPF2015.com.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Cellular Biomedicine Group Inc. Logo

Help employers find you! Check out all the jobs and post your resume.

Back to news